“原料-制剂一体化”见效，回盛生物前三季净利同比增近5倍

Core Viewpoint - The company, Huisheng Biological, reported significant growth in revenue and net profit for the first three quarters of the year, driven by increased product sales despite challenges in the swine breeding industry [1][2] Financial Performance - Revenue for the first three quarters reached approximately 1.26 billion yuan, a year-on-year increase of 58.92% [1] - Net profit attributable to shareholders was about 188 million yuan, up 494.28% year-on-year [1] - In Q3 alone, revenue was 437 million yuan, reflecting a 22.76% increase year-on-year, while net profit soared to 70.72 million yuan, a staggering 1575.79% increase [1] Business Strategy - The implementation of a raw material and formulation integration strategy has significantly enhanced the company's competitiveness and profitability [2] - The raw material business saw substantial revenue growth compared to the previous year, indicating successful strategic execution [2] Market Development - The company is focusing on innovation in microbial fermentation to improve production efficiency and product quality, while also expanding its domestic and international market presence [2] - The overseas market is primarily driven by raw material exports, with formulation exports still in the exploratory phase [2] Capacity Expansion - The company announced plans to invest 170 million yuan in upgrading its veterinary raw material production lines, aimed at enhancing production capacity and energy efficiency [2] - The upgrade will involve the introduction of high-efficiency, automated equipment and will focus on reducing waste and improving resource utilization [2]